Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study.

Miguel RegueiroMonika FischerPeter BossuytKim McGinnisMarijana ProticTheresa Hunter GibbleTommaso PanniLai Shan ChanToshifumi HibiDavid T Rubin

Published in: Inflammatory bowel diseases (2024)

Mirikizumab treatment significantly improved fatigue in patients with moderately to severely active CD, which was sustained to W104. The improvement in fatigue was correlated with improvement in clinical measures and was strongly correlated with improvement in QoL.

Keyphrases

sleep quality
depressive symptoms
physical activity
combination therapy